Erratum: Can personalized drug therapy be achieved? A closer look at pharmaco-metabonomics. Trends Pharmacol. Sci. 27 (2006) 580-586 (DOI:10.1016/j.tips.2006.09.008);Can personalized drug therapy be achieved? A closer look at pharmaco-metabonomics

Trends in Pharmacological Sciences

Volumn 27, Issue 11, 2006, Pages 580-586

  Nebert, Daniel W ^a   Vesell, Elliot S ^b  

^a Division of Human Genetics   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; COMPLEMENTARY DNA; CYTOCHROME P450 2D6; ERYTHROMYCIN; MERCAPTOPURINE; NAPROXEN; PARACETAMOL; PROPRANOLOL; TACRINE; THEOPHYLLINE; THIOPURINE METHYLTRANSFERASE; VERAPAMIL;

ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; CLINICAL PHARMACOLOGY; DNA BINDING; DNA MICROARRAY; DNA POLYMORPHISM; DOSE CALCULATION; DRUG CYTOTOXICITY; DRUG DISPOSITION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; DRUG TREATMENT FAILURE; DRUG URINE LEVEL; ELECTROCHEMICAL ANALYSIS; GENE LOCUS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMOZYGOTE; HUMAN; INTRON; LIVER TOXICITY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PENETRANCE; PHARMACOGENOMICS; PRIORITY JOURNAL; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTOMICS;

EID: 33750202863     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2006.12.009     Document Type: Erratum

References (54)

1. Nebert D.W., and Vesell E.S. Advances in pharmacogenomics and individualized drug therapy: exciting challenges that lie ahead. Eur. J. Pharmacol. 500 (2004) 267-280
2. Nebert D.W., et al. Pharmacogenomics and 'individualized drug therapy': high expectations and disappointing achievements. Am. J. Pharmacogenomics 3 (2003) 361-370
3. Wang L., and Weinshilboum R. Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene 25 (2006) 1629-1638
4. van Aken J., et al. Prospects and limits of pharmacogenetics: the thiopurine methyl transferase (TPMT) experience. Am. J. Pharmacogenomics 3 (2003) 149-155
5. Nelson D.R., et al. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14 (2004) 1-18
6. Nebert D.W., and Russell D.W. Clinical importance of the cytochromes P450. Lancet 360 (2002) 1155-1162
7. Binder E.B., and Holsboer F. Pharmacogenomics and antidepressant drugs. Ann. Med. 38 (2006) 82-94
8. Eaton D.L., et al. Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics 5 (1995) 259-274
9. Nebert D.W., et al. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol. 15 (1996) 273-280
10. Jiang Z., et al. Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype. Pharmacogenet. Genomics 16 (2006) 359-367
11. Wang S., and Cheng Q. Microarray analysis in drug discovery and clinical applications. Methods Mol. Biol. 316 (2006) 49-65
12. Verducci J.S., et al. Microarray analysis of gene expression: considerations in data mining and statistical treatment. Physiol. Genomics 25 (2006) 355-363
13. Wu X., and Dewey T.G. From microarray to biological networks: Analysis of gene expression profiles. Methods Mol. Biol. 316 (2006) 35-48
14. Righetti P.G., et al. Proteome analysis in the clinical chemistry laboratory: myth or reality?. Clin. Chim. Acta 357 (2005) 123-139
15. Kozarova A., et al. Array of informatics: Applications in modern research. J. Proteome Res. 5 (2006) 1051-1059
16. Kolch W., et al. The molecular make-up of a tumour: proteomics in cancer research. Clin. Sci. (Lond.) 108 (2005) 369-383
17. Xing Y., et al. The multiassembly problem: reconstructing multiple transcript isoforms from EST fragment mixtures. Genome Res. 14 (2004) 426-441
18. Clayton T.A., et al. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440 (2006) 1073-1077
19. Plumb R.S., et al. Metabonomics: the use of electrospray mass spectrometry coupled to reversed-phase liquid chromatography shows potential for the screening of rat urine in drug development. Rapid Commun. Mass Spectrom. 16 (2002) 1991-1996
20. Nicholson J.K., et al. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 29 (1999) 1181-1189
21. Aardema M.J., and MacGregor J.T. Toxicology and genetic toxicology in the new era of "toxicogenomics": impact of "-omics" technologies. Mutat. Res. 499 (2002) 13-25
22. Shockcor J.P., and Holmes E. Metabonomic applications in toxicity screening and disease diagnosis. Curr. Top. Med. Chem. 2 (2002) 35-51
23. Nicholson J.K., et al. Metabonomics: a platform for studying drug toxicity and gene function. Nat. Rev. Drug Discov. 1 (2002) 153-161
24. Smith L.L. Key challenges for toxicologists in the 21st century. Trends Pharmacol. Sci. 22 (2001) 281-285
25. Reo N.V. NMR-based metabolomics. Drug Chem. Toxicol. 25 (2002) 375-382
26. Griffin J.L. Metabonomics: NMR spectroscopy and pattern recognition analysis of body fluids and tissues for characterisation of xenobiotic toxicity and disease diagnosis. Curr. Opin. Chem. Biol. 7 (2003) 648-654
27. Lindon J.C., et al. Metabonomics: systems biology in pharmaceutical research and development. Curr. Opin. Mol. Ther. 6 (2004) 265-272
28. Wilson I.D., et al. HPLC-MS-based methods for the study of metabonomics. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 817 (2005) 67-76
29. Ekins S., et al. Techniques: application of systems biology to absorption, distribution, metabolism, excretion and toxicity. Trends Pharmacol. Sci. 26 (2005) 202-209
30. Lindon J.C., et al. Metabonomics and its role in drug development and disease diagnosis. Expert Rev. Mol. Diagn. 4 (2004) 189-199
31. Reynolds V.L. Applications of emerging technologies in toxicology and safety assessment. Int. J. Toxicol. 24 (2005) 135-137
32. Keun H.C. Metabonomic modeling of drug toxicity. Pharmacol. Ther. 109 (2006) 92-106
33. Lindon J.C., et al. The Consortium for Metabonomic Toxicology (COMET): aims, activities and achievements. Pharmacogenomics 6 (2005) 691-699
34. Lindon J.C., et al. Metabonomics techniques and applications to pharmaceutical research & development. Pharm. Res. 23 (2006) 1075-1088
35. Ackermann B.L., et al. The role of mass spectrometry in biomarker discovery and measurement. Curr. Drug Metab. 7 (2006) 525-539
36. Holmes E., et al. The application of NMR-based metabonomics in neurological disorders. NeuroRx. 3 (2006) 358-372
37. Plumb R., et al. Metabonomic analysis of mouse urine by liquid-chromatography-time of flight mass spectrometry (LC-tof-MS): detection of strain, diurnal and gender differences. Analyst 128 (2003) 819-823
38. Idborg-Bjorkman H., et al. Screening of biomarkers in rat urine using LC/electrospray ionization-MS and two-way data analysis. Anal. Chem. 75 (2003) 4784-4792
39. Hop C.E., et al. In vitro metabolite identification using fast gradient high performance liquid chromatography combined with tandem mass spectrometry. Rapid Commun. Mass Spectrom. 16 (2002) 212-219
40. Ayrton J., et al. Ultra-high flow rate capillary liquid chromatography with mass spectrometric detection for the direct analysis of pharmaceuticals in plasma at sub-nanogram per millilitre concentrations. Rapid Commun. Mass Spectrom. 13 (1999) 1657-1662
41. Plumb R.S., et al. Use of liquid chromatography/time-of-flight mass spectrometry and multivariate statistical analysis shows promise for the detection of drug metabolites in biological fluids. Rapid Commun. Mass Spectrom. 17 (2003) 2632-2638
42. Plumb R.S., et al. A rapid screening approach to metabonomics using UPLC and oa-TOF mass spectrometry: application to age, gender and diurnal variation in normal/Zucker obese rats and black, white and nude mice. Analyst 130 (2005) 844-849
43. Johnson K.A., and Plumb R. Investigating the human metabolism of acetaminophen using UPLC and exact mass oa-TOF MS. J. Pharm. Biomed. Anal. 39 (2005) 805-810
44. Wilson I.D., et al. High resolution "ultra performance" liquid chromatography coupled to oa-TOF mass spectrometry as a tool for differential metabolic pathway profiling in functional genomic studies. J. Proteome Res. 4 (2005) 591-598
45. Nicholson J.K., and Wilson I.D. Opinion: understanding 'global' systems biology: metabonomics and the continuum of metabolism. Nat. Rev. Drug Discov. 2 (2003) 668-676
46. Lindon J.C., et al. NMR spectroscopy of biofluids. In: Webb G.A. (Ed). Annu Reports NMR Spectr (1999), Academic Press 1-88
47. German J.B., et al. Genomics and metabolomics as markers for the interaction of diet and health: lessons from lipids. J. Nutr. 133 (2003) 2078S-2083S
48. 1H-NMR-based metabonomics. Nat. Med. 8 (2002) 1439-1444
49. Sabatine M.S., et al. Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation 112 (2005) 3868-3875
50. Becker R.C. Preoteomics, metabolomics and circulating endothelial progenitor cells in acute coronary syndromes. J. Thromb. Thrombolysis 21 (2006) 203-206
51. 1H-NMR spectroscopy combined with pattern recognition analysis reveals characteristic chemical patterns in urines of MS patients and non-human primates with MS-like disease. J. Neurol. Sci. 212 (2003) 21-30
52. 1H NMR and HPLC-MS-based metabonomic study of urine from obese (fa/fa) Zucker and normal Wistar-derived rats. J. Pharm. Biomed. Anal. 38 (2005) 465-471
53. Crockford D.J., et al. Statistical heterospectroscopy, an approach to the integrated analysis of NMR and UPLC-MS data sets: application in metabonomic toxicology studies. Anal. Chem. 78 (2006) 363-371
54. 1H NMR data sets. Anal. Chem. 77 (2005) 1282-1289